Skip to main content
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1989 Sep;33(9):1606–1608. doi: 10.1128/aac.33.9.1606

Antagonism of the cytotoxic but not antiviral effects of ara-sangivamycin by adenosine.

G M Birch 1, S H Krawczyk 1, L B Townsend 1, J C Drach 1
PMCID: PMC172710  PMID: 2554803

Abstract

Inhibition of DNA synthesis by ara-sangivamycin was antagonized by adenosine. The 50% inhibitory concentrations increased 1.6- to 32-fold in the presence of 1.0 to 50 microM adenosine, respectively. In contrast, the inhibition of human cytomegalovirus replication by ara-sangivamycin was not antagonized by as much as 50 microM adenosine. This suggests that different enzymes were responsible for the phosphorylation of ara-sangivamycin in uninfected and infected cells.

Full text

PDF
1606

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Biron K. K., Fyfe J. A., Stanat S. C., Leslie L. K., Sorrell J. B., Lambe C. U., Coen D. M. A human cytomegalovirus mutant resistant to the nucleoside analog 9-([2-hydroxy-1-(hydroxymethyl)ethoxy]methyl)guanine (BW B759U) induces reduced levels of BW B759U triphosphate. Proc Natl Acad Sci U S A. 1986 Nov;83(22):8769–8773. doi: 10.1073/pnas.83.22.8769. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Colacino J. M., Lopez C. Efficacy and selectivity of some nucleoside analogs as anti-human cytomegalovirus agents. Antimicrob Agents Chemother. 1983 Oct;24(4):505–508. doi: 10.1128/aac.24.4.505. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Davis M. G., Kenney S. C., Kamine J., Pagano J. S., Huang E. S. Immediate-early gene region of human cytomegalovirus trans-activates the promoter of human immunodeficiency virus. Proc Natl Acad Sci U S A. 1987 Dec;84(23):8642–8646. doi: 10.1073/pnas.84.23.8642. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Estes J. E., Huang E. S. Stimulation of cellular thymidine kinases by human cytomegalovirus. J Virol. 1977 Oct;24(1):13–21. doi: 10.1128/jvi.24.1.13-21.1977. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Field A. K., Davies M. E., DeWitt C., Perry H. C., Liou R., Germershausen J., Karkas J. D., Ashton W. T., Johnston D. B., Tolman R. L. 9-([2-hydroxy-1-(hydroxymethyl)ethoxy]methyl)guanine: a selective inhibitor of herpes group virus replication. Proc Natl Acad Sci U S A. 1983 Jul;80(13):4139–4143. doi: 10.1073/pnas.80.13.4139. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Freitas V. R., Smee D. F., Chernow M., Boehme R., Matthews T. R. Activity of 9-(1,3-dihydroxy-2-propoxymethyl)guanine compared with that of acyclovir against human, monkey, and rodent cytomegaloviruses. Antimicrob Agents Chemother. 1985 Aug;28(2):240–245. doi: 10.1128/aac.28.2.240. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Henderson J. F., Brox L., Zombor G., Hunting D., Lomax C. A. Specificity of adenosine deaminase inhibitors. Biochem Pharmacol. 1977 Nov 1;26(21):1967–1972. doi: 10.1016/0006-2952(77)90003-x. [DOI] [PubMed] [Google Scholar]
  8. Jacobson M. A., Mills J. Serious cytomegalovirus disease in the acquired immunodeficiency syndrome (AIDS). Clinical findings, diagnosis, and treatment. Ann Intern Med. 1988 Apr;108(4):585–594. doi: 10.7326/0003-4819-108-4-585. [DOI] [PubMed] [Google Scholar]
  9. Krenitsky T. A., Tuttle J. V., Koszalka G. W., Chen I. S., Beacham L. M., 3rd, Rideout J. L., Elion G. B. Deoxycytidine kinase from calf thymus. Substrate and inhibitor specificity. J Biol Chem. 1976 Jul 10;251(13):4055–4061. [PubMed] [Google Scholar]
  10. Lamberson H. V., Jr Cytomegalovirus (CMV): the agent, its pathogenesis, and its epidemiology. Prog Clin Biol Res. 1985;182:149–173. [PubMed] [Google Scholar]
  11. Mar E. C., Patel P. C., Cheng Y. C., Fox J. J., Watanabe K. A., Huang E. S. Effects of certain nucleoside analogues on human cytomegalovirus replication in vitro. J Gen Virol. 1984 Jan;65(Pt 1):47–53. doi: 10.1099/0022-1317-65-1-47. [DOI] [PubMed] [Google Scholar]
  12. Meyers J. D., Reed E. C., Shepp D. H., Thornquist M., Dandliker P. S., Vicary C. A., Flournoy N., Kirk L. E., Kersey J. H., Thomas E. D. Acyclovir for prevention of cytomegalovirus infection and disease after allogeneic marrow transplantation. N Engl J Med. 1988 Jan 14;318(2):70–75. doi: 10.1056/NEJM198801143180202. [DOI] [PubMed] [Google Scholar]
  13. Miller R. L., Adamczyk D. L., Miller W. H., Koszalka G. W., Rideout J. L., Beacham L. M., 3rd, Chao E. Y., Haggerty J. J., Krenitsky T. A., Elion G. B. Adenosine kinase from rabbit liver. II. Substrate and inhibitor specificity. J Biol Chem. 1979 Apr 10;254(7):2346–2352. [PubMed] [Google Scholar]
  14. Morris D. J. Antiviral chemotherapy for cytomegalovirus disease. J Antimicrob Chemother. 1988 May;21(5):519–522. doi: 10.1093/jac/21.5.519. [DOI] [PubMed] [Google Scholar]
  15. Reed E. C., Meyers J. D. Treatment of cytomegalovirus infection. Clin Lab Med. 1987 Dec;7(4):831–852. [PubMed] [Google Scholar]
  16. Ritch P. S., Glazer R. I., Cunningham R. E., Shackney S. E. Kinetic effects of sangivamycin in sarcoma 180 in vitro. Cancer Res. 1981 May;41(5):1784–1788. [PubMed] [Google Scholar]
  17. Ritch P. S., Helmsworth M. Pyrrolopyrimidine lethality in relation to ribonucleic acid synthesis in sarcoma 180 cells in vitro. Biochem Pharmacol. 1982 Aug 15;31(16):2686–2688. doi: 10.1016/0006-2952(82)90721-3. [DOI] [PubMed] [Google Scholar]
  18. Smith S. H., Shipman C., Jr, Drach J. C. Deoxyadenosine antagonism of the antiviral activity of 9-beta-D-arabinofuranosyladenine and 9-beta-D-arabinofuranosylhypoxanthine. Cancer Res. 1978 Jul;38(7):1916–1921. [PubMed] [Google Scholar]
  19. Turk S. R., Shipman C., Jr, Nassiri R., Genzlinger G., Krawczyk S. H., Townsend L. B., Drach J. C. Pyrrolo[2,3-d]pyrimidine nucleosides as inhibitors of human cytomegalovirus. Antimicrob Agents Chemother. 1987 Apr;31(4):544–550. doi: 10.1128/aac.31.4.544. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES